Tyratech have announced increased revenues for 2014, and are focussing more of their funding on Vamousse.
Tyratech recently announced revenue for 2014 of US$4.9m, an increase of 250% over the previous year. The increase was largely due to the increased distribution network for the company's Vamousse lice treatment. The costs of product launches resulted in a pre-tax loss of US$5.1m, an increase of US$0.7m over the prior year.
The financial results follow the announcement in April that Tyratech would reduce their stake in a joint venture with American Vanguard Corp, in order to invest a further US$0.5m in developing the Vamousse range and expanding its distribution.